ziprasidone has been researched along with cocaine in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 13 (76.47) | 29.6817 |
| 2010's | 3 (17.65) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sen, S; Sinha, N | 1 |
| Cavalli, A; De Ponti, F; Poluzzi, E; Recanatini, M | 1 |
| Li, J; Rajamani, R; Reynolds, CH; Tounge, BA | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Jia, L; Sun, H | 1 |
| Caron, G; Ermondi, G; Visentin, S | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Blakely, RD; Jansen, K; Richelson, E; Tatsumi, M | 1 |
| Cleveland, NJ; Dewitt, CD; Heard, K | 1 |
| Clifton, PG; Hartfield, AW; Moore, NA | 1 |
| Cleveland, NR; Heard, K; Krier, S | 1 |
| Hoffman, RS; Manini, AF; Pearl-Davis, MS; Wu, S | 1 |
| Alvarez, Jdo N; Carvalho, Rde C; Frussa-Filho, R; Fukushiro, DF; Ribeiro, LT; Ricardo, VP | 1 |
| Heard, K; Krier, S; Zahniser, NR | 1 |
| Baldaia, MA; Berro, LF; Frussa-Filho, R; Hollais, AW; Longo, BM; Marinho, EA; Oliveira-Lima, AJ; Santos, R; Wuo-Silva, R | 1 |
| Baldaia, MA; Berro, LF; Frussa-Filho, R; Hollais, AW; Marinho, E; Oliveira-Lima, AJ; Ribeiro, LT; Santos-Baldaia, R; Talhati, F; Wuo-Silva, R | 1 |
17 other study(ies) available for ziprasidone and cocaine
| Article | Year |
|---|---|
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go-Go Potassium Channels; Long QT Syndrome; Models, Molecular; Molecular Conformation; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2002 |
A two-state homology model of the hERG K+ channel: application to ligand binding.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Ligands; Models, Biological; Models, Molecular; Potassium Channels, Voltage-Gated; Protein Binding; Protein Conformation | 2005 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
Topics: Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Potassium Channel Blockers; Quantitative Structure-Activity Relationship | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Pharmacological profile of neuroleptics at human monoamine transporters.
Topics: Antipsychotic Agents; Carrier Proteins; Cell Line; Chlorpromazine; Cocaine; Dibenzazepines; Dibenzothiepins; Dopamine Plasma Membrane Transport Proteins; Fluoxetine; Humans; Imipramine; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Norepinephrine Plasma Membrane Transport Proteins; Pimozide; Piperazines; Protein Binding; Radioligand Assay; Recombinant Fusion Proteins; Serotonin Plasma Membrane Transport Proteins; Symporters; Thiazoles; Triflupromazine; Tritium | 1999 |
Ziprasidone pretreatment attenuates the lethal effects of cocaine in a mouse model.
Topics: Acute Disease; Animals; Antipsychotic Agents; Cocaine; Cocaine-Related Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Overdose; Injections, Intraperitoneal; Mice; Piperazines; Premedication; Random Allocation; Seizures; Single-Blind Method; Survival Analysis; Thiazoles; Treatment Outcome | 2005 |
Effects of atypical antipsychotic drugs on intralipid intake and cocaine-induced hyperactivity in rats.
Topics: Animals; Antipsychotic Agents; Cocaine; Dibenzothiazepines; Dopamine Antagonists; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Eating; Fat Emulsions, Intravenous; Female; Hyperkinesis; Male; Motor Activity; Piperazines; Quetiapine Fumarate; Rats; Risperidone; Thiazoles | 2006 |
Ziprasidone, diazepam, or the combination for prevention of cocaine toxicity in a mouse model.
Topics: Animals; Cocaine; Cocaine-Related Disorders; Confidence Intervals; Diazepam; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Male; Mice; Mice, Inbred Strains; Piperazines; Random Allocation; Reference Values; Sensitivity and Specificity; Statistics, Nonparametric; Survival Rate; Thiazoles | 2007 |
Use of antipsychotics to treat cocaine toxicity?
Topics: Animals; Antipsychotic Agents; Cocaine; Cocaine-Related Disorders; Diazepam; Disease Models, Animal; Mice; Piperazines; Thiazoles; Treatment Outcome | 2008 |
Haloperidol (but not ziprasidone) withdrawal potentiates sensitization to the hyperlocomotor effect of cocaine in mice.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Cocaine; Cocaine-Related Disorders; Haloperidol; Humans; Male; Mice; Motor Activity; Piperazines; Schizophrenia; Substance Withdrawal Syndrome; Thiazoles | 2008 |
Administration of ziprasidone for 10 days increases cocaine toxicity in mice.
Topics: Animals; Antipsychotic Agents; Cocaine; Cocaine-Related Disorders; Disease Models, Animal; Dopamine Uptake Inhibitors; Drug Synergism; Longevity; Male; Mice; Mice, Inbred Strains; Piperazines; Seizures; Thiazoles; Time Factors; Withholding Treatment | 2008 |
Selective action of an atypical neuroleptic on the mechanisms related to the development of cocaine addiction: a pre-clinical behavioural study.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Central Nervous System Sensitization; Cocaine; Cocaine-Related Disorders; Disease Models, Animal; Dopamine Antagonists; Dopamine Uptake Inhibitors; Haloperidol; Male; Mice; Motor Activity; Piperazines; Quinolones; Thiazoles | 2014 |
Context-dependent efficacy of a counter-conditioning strategy with atypical neuroleptic drugs in mice previously sensitized to cocaine.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Cocaine; Conditioning, Operant; Dopamine Uptake Inhibitors; Exploratory Behavior; Hyperkinesis; Locomotion; Male; Mice; Piperazines; Statistics, Nonparametric; Thiazoles | 2017 |